Search results
Results From The WOW.Com Content Network
File:Novartis-Logo.svg. Size of this PNG preview of this SVG file: 512 × 84 pixels. Other resolutions: 320 × 53 pixels | 640 × 105 pixels | 1,024 × 168 pixels | 1,280 × 210 pixels | 2,560 × 420 pixels. Original file (SVG file, nominally 512 × 84 pixels, file size: 2 KB) This is a file from the Wikimedia Commons.
MLU3LU3EVV. KEGG. D11559. Onasemnogene abeparvovec, sold under the brand name Zolgensma, is a gene therapy used to treat spinal muscular atrophy (SMA), [6] [7] a disease causing muscle function loss in children. It involves a one-time infusion of the medication into a vein. [6] It works by providing a new copy of the SMN gene that produces the ...
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer ( adoptive cell transfer ). [9] [7]
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
BeiGene. BeiGene, Ltd. is a China-based drug developer. [3] It specializes in the development of drugs for cancer treatment. [4] Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the multinational company headquartered in Cambridge, Massachusetts has offices in North America, Europe, South America, Asia and Australia.
KEGG. D11008. Voretigene neparvovec, sold under the brand name Luxturna, is a gene therapy medication for the treatment of Leber congenital amaurosis. [4] Leber's congenital amaurosis, or biallelic RPE65 -mediated inherited retinal disease, is an inherited disorder causing progressive blindness. Voretigene is the first treatment available for ...
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
The Novartis Foundation was a scientific and educational charity, formed in 1949 by the Swiss company Ciba, now Novartis, and dissolved in 2008. It was the direct successor to the Ciba Foundation, and the changed name (Novartis Foundation) reflected the new name of Ciba, after merging with Sandoz. The Foundation was the brainchild of Robert ...